Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and Financial Results Conference Call on March 10, 2021 at 4:00 p.m. ET

DALLAS, March 3, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve cancer drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Wednesday, March 10, 2021 at 4:00 p.m. ET to discuss financial and operating results for the fourth quarter and fiscal year ended December 31, 2020.

The call will be led by Panna Sharma, President and Chief Executive Officer. He will be joined on the call by other members of the management team. Interested participants and investors may access the conference call via teleconference or online.

Conference Call & Webcast Details               
Toll-free Domestic & Canada: 877.830.2592 conference ID: 61024
International: 785.424.1739 – conference ID 61024
US and Canada callers one touch dial: +1. 877.830.2592,, 61024#
Live audio-only webcast and related presentation materials will also be accessible at: Web participants should register 15 minutes prior to the start of the call. The webcast will be archived on the Lantern Pharma website for 45 days.

Replay Details
A replay of the conference call will be available through 11:59 p.m. ET on April 10, 2021.
Replay Toll-free Domestic & Canada: 1.800.938.2795 – passcode: 61024
Replay International: 1.402.220.9029 – passcode: 61024

About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the revitalization, refocusing and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using our proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at or follow the company on Twitter @lanternpharma.

Marek Ciszewski, JD
Director, Investor Relations

Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates; (iii) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (iv) those other factors set forth in the Risk Factors section in our final prospectus, dated January 14, 2021, for our follow-on public offering, on file with the Securities and Exchange Commission. You may access our January 14, 2021 final prospectus under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. 


Cision View original content to download multimedia:

SOURCE Lantern Pharma